muramyl tripeptide phosphatidyl ethanolamine
Small moleculeexperimental
Clinical trial activity
5 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00001042)
Timeline
Indications
Mechanism of action
NOD2 other
Immunostimulant
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC- Mol. weight
- 1237.52 g/mol
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2111100 ↗
- ChEMBLCHEMBL2107354 ↗
Also known as
- cgp 19835 a
- cgp-19835a
- junovan
- l-alaninamide, n-(n-acetylmuramoyl)-l-alanyl-d-alpha-glutaminyl-n-(4-hydroxy-10-oxo-7-((1-oxohexadecyl)oxy)-3,5,9-trioxa-4-phosphapentacos-1-yl)-, p-oxide, (r)-
- l-mtp-pe
- l-mtp-pe
- l-mtp-pe
- mepact
- mepact
- mifamurtide
- mifamurtide
- mifamurtide
- mifamurtide
- mifamurtide
- mifamurtide
- mifamurtide
- mifamurtide acid
- mifamurtide anhydrous
- mifamurtide free acid anhydrous
- mifamurtide hydrate
- mifamurtide sodium
- mifamurtide sodium
- mifamurtide sodium hydrate
- mifamurtide sodium salt
- mlv 19835
- mtp-pe
- mtp-pe
- mtp-pe
- mtp-pe
- mtp-pe
- muramylnac-ala-isogln-lys-tripeptide-pe
- muramylnac-ala-isogln-lys-tripeptide-phosphatidylethanolamine
- muramyl tripeptide-1,2-dipalmitoylphosphatidylethanolamine conjugate
- muramyl tripeptide-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine conjugate
- muramyl tripeptide phosphatidylethanolamine
- muramyl tripeptide phosphatidyl ethanolamine
- muramyl tripeptide phosphatidylethanolamine, monosodium salt
- muramyl tripeptide phosphatidylethanolamine, sodium salt
- n-acetylmuramyl-alanyl-isoglutaminyl-alanyl-sn-glycero-3-phosphoethanolamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03643133 | Phase 2 | Aug 31, 2018 | Curie Institute, Institut Gustave Roussy, UNICANCER |
| NCT02441309 | Phase 2 | Oct 1, 2014 | European Commission, National Institute for Health Research, United Kingdom, Takeda, University of Oxford |
| NCT01459484 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2011 | Italian Sarcoma Group |
| NCT00001042 | Phase 1 | Nov 2, 1999 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT04571229 | N/A | — | Memorial Sloan-Kettering Cancer Center |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Curie Institute | Academic/Hospital | 1 | 0 | 1 | 2018 |
| European Commission | Government | 1 | 0 | 1 | 2014 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Italian Sarcoma Group | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | — |
| National Institute for Health Research, United Kingdom | Government | 1 | 0 | 1 | 2014 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1999 |
| Takeda | For profit | 1 | 0 | 1 | 2014 |
| UNICANCER | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2014 |
10 organizations
Page 1 / 1